Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe record describes the Phase 1 CTX130 study for relapsed or refractory T- or B-cell malignancies, including its terminated status, eligibility criteria, study locations, interventions, and outcome measures.SummaryDifference44%

- Check18 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check25 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check32 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page content remains a 403 error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe page remains a 403 Forbidden error page. Its footer revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedNow the page displays a 403 Forbidden error, blocking access to the study record instead of showing the study details. This indicates an access-control issue rather than an update to the study information.SummaryDifference17%

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.